Fine, Kaplan and Black Announces Settlement in Class Action for Prescription Drug Payments
On October 3, 2025, Fine, Kaplan and Black, R.P.C. made a significant announcement regarding a class action lawsuit settlement focused on prescription generic drugs. The suit pertains to individuals who made payments or obtained reimbursements for specific prescription generic medications within the United States between May 1, 2009, and December 31, 2019. The settlement involves a total sum of $200 million designated to compensate eligible claimants.
The origins of the lawsuit can be traced back to allegations asserting that generic drug manufacturers engaged in practices that violated federal and state antitrust laws, leading to inflated costs for end-payers. This affected not only consumers but also third-party payers, such as insurance companies. The primary defendants in this action included Sun Pharmaceutical Industries and Taro Pharmaceuticals, collectively referred to as Sun/Taro. These companies have denied any wrongdoing.
If you believe you may qualify for this settlement, take note that the eligibility criteria are outlined clearly. Affected individuals are those who, within the specified time frame, either, directly or indirectly, purchased or paid for these medications for personal use. Exclusions apply to certain entities, therefore it's essential to check the detailed criteria available on the official settlement website: www.GenericDrugsEndPayerSettlement.com.
Upon approval of this settlement by the court, distributions from the settlement fund will be processed. It’s highlighted that this fund may be reduced under certain circumstances, and distributions will also account for administrative costs and attorneys' fees, which could amount to a third of the total fund plus interest.
Interested parties should actively register on the EPP settlement website or call the dedicated hotline for updates related to the claims process. The window for claims will officially open at a later date following final court approval. Claimants will have the chance to receive compensation, pending judicial authorization on how funds will be allocated.
For those who prefer not to be bound by the terms of the settlement, it is crucial to act swiftly. Individuals wishing to opt-out must formally submit their request by December 2, 2025. A fairness hearing is scheduled for January 15, 2026, where the court will decide on the approvals of the settlement and related expenses.
It is important to stay informed and keep an eye on the communication channels for any changes regarding deadlines or details pertinent to the settlement. For more information regarding your legal rights or the claims process, you may call the hotline at 1-877-316-0171 or visit the dedicated settlement website.
In conclusion, if you or someone you know has been affected by these practices, it is vital to explore your options under this settlement and ensure your rights are preserved throughout this complex legal process.
The origins of the lawsuit can be traced back to allegations asserting that generic drug manufacturers engaged in practices that violated federal and state antitrust laws, leading to inflated costs for end-payers. This affected not only consumers but also third-party payers, such as insurance companies. The primary defendants in this action included Sun Pharmaceutical Industries and Taro Pharmaceuticals, collectively referred to as Sun/Taro. These companies have denied any wrongdoing.
If you believe you may qualify for this settlement, take note that the eligibility criteria are outlined clearly. Affected individuals are those who, within the specified time frame, either, directly or indirectly, purchased or paid for these medications for personal use. Exclusions apply to certain entities, therefore it's essential to check the detailed criteria available on the official settlement website: www.GenericDrugsEndPayerSettlement.com.
Upon approval of this settlement by the court, distributions from the settlement fund will be processed. It’s highlighted that this fund may be reduced under certain circumstances, and distributions will also account for administrative costs and attorneys' fees, which could amount to a third of the total fund plus interest.
Interested parties should actively register on the EPP settlement website or call the dedicated hotline for updates related to the claims process. The window for claims will officially open at a later date following final court approval. Claimants will have the chance to receive compensation, pending judicial authorization on how funds will be allocated.
For those who prefer not to be bound by the terms of the settlement, it is crucial to act swiftly. Individuals wishing to opt-out must formally submit their request by December 2, 2025. A fairness hearing is scheduled for January 15, 2026, where the court will decide on the approvals of the settlement and related expenses.
It is important to stay informed and keep an eye on the communication channels for any changes regarding deadlines or details pertinent to the settlement. For more information regarding your legal rights or the claims process, you may call the hotline at 1-877-316-0171 or visit the dedicated settlement website.
In conclusion, if you or someone you know has been affected by these practices, it is vital to explore your options under this settlement and ensure your rights are preserved throughout this complex legal process.
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.